Maude Bouscambert
Overview
Explore the profile of Maude Bouscambert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parraud D, Maucotel A, Bouscambert M, Morfin F, Bitker L, Chidiac C, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243128
Qualitative SARS-CoV-2 antigen assays based on immunochromatography are useful for mass diagnosis of COVID-19, even though their sensitivity is poor in comparison with RT-PCR assays. In addition, quantitative assays could...
2.
Amstutz A, Speich B, Mentre F, Rueegg C, Belhadi D, Assoumou L, et al.
Lancet Respir Med
. 2023 Feb;
11(5):453-464.
PMID: 36828006
Background: Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of...
3.
Merad Y, Gaymard A, Cotte L, Perpoint T, Alfaiate D, Godinot M, et al.
Euro Surveill
. 2023 Jan;
27(50).
PMID: 36695469
Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108...
4.
Troseid M, Arribas J, Assoumou L, Holten A, Poissy J, Terzic V, et al.
Crit Care
. 2023 Jan;
27(1):9.
PMID: 36627655
Background: Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods: Bari-SolidAct is a phase-3, multicentre, randomised,...
5.
Sentis C, Billaud G, Bal A, Frobert E, Bouscambert M, Destras G, et al.
Viruses
. 2022 May;
14(5).
PMID: 35632661
Objectives: High viral load in upper respiratory tract specimens observed for Delta cases might contribute to its increased infectivity compared to the other variant. However, it is not yet documented...
6.
Bal A, Brengel-Pesce K, Gaymard A, Queromes G, Guibert N, Frobert E, et al.
Sci Rep
. 2021 Sep;
11(1):19317.
PMID: 34556795
No abstract available.
7.
Bal A, Brengel-Pesce K, Gaymard A, Queromes G, Guibert N, Frobert E, et al.
Sci Rep
. 2021 Jul;
11(1):14977.
PMID: 34294751
A comprehensive clinical and microbiological assessments of COVID-19 in front-line healthcare workers (HCWs) is needed. Between April 10th and May 28th, 2020, 319 HCWs with acute illness were reviewed. In...
8.
Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al.
Euro Surveill
. 2021 Jan;
26(3).
PMID: 33478625
We report the strategy leading to the first detection of variant of concern 202012/01 (VOC) in France (21 December 2020). First, the spike (S) deletion H69-V70 (ΔH69/ΔV70), identified in certain...
9.
Casalegno J, Bouscambert M, Lina B
Virologie (Montrouge)
. 2020 Oct;
18(3):151-169.
PMID: 33065849
Avian Influenza viruses emergences are more frequent than pandemic events. Since 1976 several cases of human infections with avian or swine Influenza, such as H1, H3, H5, H6, H7, H9,...
10.
Etievant S, Bal A, Escuret V, Brengel-Pesce K, Bouscambert M, Cheynet V, et al.
J Clin Med
. 2020 Jun;
9(6).
PMID: 32560044
A reliable diagnostic assay is crucial to early detect new COVID-19 cases and limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Since the onset of the COVID-19 pandemic, the...